Management of Hyperlipidemia with Chronic Kidney Disease

Risk Stratification

• The European Society of Cardiology recommends that patients with Stage 3b CKD (eGFR 44 mL/min/1.73 m²) be considered at high to very high cardiovascular risk 1, 2, 3
• The European Society of Cardiology also states that LDL-C levels above target for CKD patients, such as 121 mg/dL, indicate high cardiovascular risk 1, 2
• Non-HDL cholesterol levels, such as 143 mg/dL, are also considered elevated and contribute to high cardiovascular risk 2

Lipid Management Strategy

• The European Society of Cardiology recommends starting moderate-to-high intensity statin therapy immediately in patients with non-dialysis-dependent CKD, with a target LDL-C of <100 mg/dL 1, 2, 3, 6
• The target non-HDL-C is <130 mg/dL, and statin/ezetimibe combination is specifically indicated for non-dialysis-dependent CKD 1, 2, 3

Renal Function Management

• The Kidney International journal suggests initiating ACE inhibitor or ARB therapy if blood pressure is elevated or if proteinuria develops, with a target BP of 120-129/70-79 mmHg 4, 6
• The Kidney International journal also recommends monitoring renal function and potassium within 2-4 weeks after starting ACE inhibitor or ARB therapy 4

Lifestyle Modifications

• The Kidney International journal recommends implementing comprehensive lifestyle changes, including dietary sodium restriction to <2.0 g/day, plant-based diet, regular exercise, weight normalization, and smoking cessation 4, 9, 5

Common Pitfalls to Avoid

• The European Society of Cardiology states that statins should not be withheld in CKD patients, as the evidence strongly supports statin use in non-dialysis-dependent CKD 1, 2, 3, 6
• The Kidney International journal advises monitoring for statin-related myopathy carefully in CKD, as the risk may be increased with renal impairment 7, 10, 4